Had a conversation with someone outside of healthcare recently who was shocked by how long it takes to run clinical trials in the U.S (not to mention expensive). I tried to explain—it’s not just the science. It’s the infrastructure. Every site needs dozens of personnel, many of

Great fully funded PhD opportunity to work with me (QUB Public Health) and Valerie McCormack (IARC) on ESCC in Africa. IARC placement in Lyon included! UK home students eligible. Please share: findaphd.com/phds/project/i…

Pragmatic Approach to Hepatocellular Carcinoma Diagnosis in High-Incidence, Resource-Limited Settings in Africa. Read the full article. brnw.ch/21wTtNN

📊 Are we overestimating success in ph3 oncology trials? 📉 Only 6% of ph3 oncology RCTs show improvement in both OS and QoL. Most “positive” trials rely on surrogate endpoints, often without adjusting QoL for baseline. We must refocus trials on what truly matters to patients.

Middle East and North African countries are underrepresented in oncology clinical trials, with higher participation in observational, late-phase, and industry-funded trials, and greater representation in countries with higher GDP. ja.ma/4jWY8nQ

In today's episode of #Ask #Uganda #Cancer #Institute, we tackle #Oesophageal cancer risk factors and prevention. Note: Oesophagus is the tube that connects the throat to the stomach. #FightCancerUg Grab a copy of Daily Monitor for more.

🚨 Big news: AORTIC 🤝 Bio Usawa lnc! We’ve signed an #MoU to boost Africa’s #cancercare via: 🧪 Women’s health research 🎓 Capacity-building 💡 Microgrants for local researchers Made in Africa. Led by Africans. For Africans. tinyurl.com/AORTICBioUsawa #AORTIC #HealthEquity

🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to: 🔹 Colorectal: +103% 🔹 Pancreatic: +100% 🔹 Esophageal: +86% 🔹 Liver: +81% 🌍 Biggest increases in Asia & Africa 💡 Call to action: Early detection, access, equity. Time for GI oncologist

📢📢Esophageal cancer: What you can do? 🛑Pay attention to your body, if you have difficult swallowing, weight loss, persistent chest pain, seek care early. 🛑Avoid smoking,reduce alcohol intake, let hot beverages cool be4 drinking & 🛑Maintain good oral hygiene Daily Monitor

Wide variation in TNT regimens for rectal cancer in Europe. Variation IMO good, as treatment should be tailored to tumor features & pt preferences – not one size fits all. Reassuring that on matched analyses, no OS difference b/w different regimens. jamanetwork.com/journals/jamao…

Novel cell therapies to treat solids cancers will be a huge challenge to EU health systems; cost, accessibility and clinical expertise will need to be carefully traded off. Here we describe a model to help policymakers do just that. sciencedirect.com/science/articl… ASCO AACR ESMO - Eur. Oncology

Thrilled to see our work on oral metronomic chemotherapy featured by Prof. David Kerr (University of Oxford) on MEDSCAPE ! 📰 “The Global Applicability of Oral Metronomic Chemotherapy” 🔗 medscape.com/viewarticle/gl… Pushing the boundaries to equitable cancer care! #GlobalOnco Tata Memorial Centre, Varanasi (MPMMCC & HBCH)

It’s my great honor to write the editorial for the pivotal MATTERHORN study NEJM Yelena Y. Janjigian MD ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.OncoAlert OncoDaily nejm.org/doi/full/10.10…

🚨 Patterns of recurrence in esophageal adenocarcinoma comparing FLOT vs CROSS— ESOPEC trial update 💥 ascopubs.org/doi/10.1200/JC… ▪️Locoregional recurrence (3-yr CI): FLOT 20.2% vs CROSS 17.4% (NS) ▪️Distant recurrence (3-yr CI): FLOT 31.5% vs CROSS 47.2% (p=.002) CROSS-ing paths,

Screening for Financial Toxicity and Health-Related Social Risks in Patients With GI Cancer: Results From a Large Cancer Center. Co-authored by Kaitlyn Lapen, Edward Christopher "Chris" Dee, MD, and Fumiko Ladd Chino, MD, FASCO. Read the full article. brnw.ch/21wUdvz

Excellent study just out in ESMO GI Onc- 📊 Among 15 CLDN18.2⁺ gastric cancer pts treated w/ zolbetuximab: 🔹 53.3% lost CLDN18.2 ≥75% at progression 🔹 66.7% retained ≥40% 🔹 73.3% retained ≥25% 💡 Patients may still be eligible for next-gen CLDN18.2-targeted therapies

A final piece of advice from Holly Butcher - written the day before she passed away from cancer at just 27: “It’s a strange thing knowing you’re going to die young. At 26, I thought I had time… To fall in love. Start a family. Grow old. But cancer doesn’t care about plans.

Implications of BRAF V600E in dMMR/MSI-H pts treated with ICIs. Prognostic impact of the BRAF V600E mutation in patients with MSI-high... sciencedirect.com/science/articl… AACR Journal of Clinical Oncology ASCO Mayo Clinic Comprehensive Cancer Center

In this new piece just published in The Lancet Digital Health we argue why we have one shot at trust with medical AI, and how we’re at risk of blowing it due to poor communication and study design. Danielle Bitterman, MD Julian Hong 1/3 thelancet.com/callback?red_u…

Imperative to think about the unique needs of these patients.